UTI - Nifty Next 50 Index Fund

A Equity Funds scheme from UTI Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF789FC12T1).

NAV ₹26.9607 on 16 November 2026.

Expense ratio

Total expense ratio 0.46% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.31%, brokerage 0.00%, transaction costs 0.00%, statutory levies including GST 0.15%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year4.6%18.1%-14.4%-0.13-0.12
3 years16.8%18.7%-26.4%0.530.46
5 years11.0%18.0%-26.4%0.220.19

Too little NAV history for the 10-year figures.

Not ranked in its category: its category mixes funds too different to rank against one another.

Largest holdings

Top 10 (September 2026 disclosure). Company shares make up 100.0% of the portfolio.

  1. Divi's Laboratories Limited — 4.84%
  2. TVS Motor Company Limited — 3.95%
  3. Hindustan Aeronautics Limited — 3.63%
  4. Tata Motors Limited — 3.61%
  5. Adani Power Limited — 3.48%
  6. Samvardhana Motherson International Limited — 2.95%
  7. Torrent Pharmaceuticals Limited — 2.89%
  8. Cholamandalam Investment and Finance Company Limited — 2.88%
  9. Vedanta Aluminium Metal Limited — 2.87%
  10. Cummins India Limited — 2.63%

Plans

Other funds in Equity Funds

All 88 funds in Equity Funds · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.